BJO

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

British Journal of Ophthalmology 2005;89:1418-1419; doi:10.1136/bjo.2005.073700
Copyright © 2005 by the BMJ Publishing Group Ltd.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Prydal, J I
Right arrow Articles by Watts, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prydal, J I
Right arrow Articles by Watts, A

SCIENTIFIC REPORT

The pharmacokinetics of linezolid in the non-inflamed human eye

J I Prydal1, D R Jenkins2, A Lovering3, A Watts4

1 Department of Ophthalmic Surgery, University Hospitals of Leicester NHS Trust, Leicester LE1 5WW, UK
2 Department of Clinical Microbiology, University Hospitals of Leicester NHS Trust, Leicester LE1 5WW, UK
3 Bristol Centre for Antimicrobial Research and Evaluation, Southmead Hospital, Bristol BS10 5NB, UK
4 Department of Ophthalmic Surgery, University Hospitals of Leicester NHS Trust, Leicester LE1 5WW, UK

Correspondence to:
Correspondence to:
Jeremy Prydal
Department of Ophthalmic Surgery, University Hospitals of Leicester NHS Trust, Infirmary Square, Leicester LE1 5WW, UK; jip{at}prydal.co.uk


ABSTRACT
Aim: This study describes the ocular pharmacokinetics of linezolid, an antibiotic with broad spectrum activity against those Gram positive bacteria that are the most frequent cause of postoperative endophthalmitis.

Method: Patients undergoing routine cataract surgery were given a single oral 600 mg dose of linezolid at a variable time before surgery. Aqueous and serum levels of linezolid were assayed by high performance liquid chromatography, and a pharmacokinetic curve constructed from the pooled results.

Results: Orally administered linezolid rapidly achieves levels in the aqueous of non-inflamed eyes that exceed the concentration required to kill Gram positive bacteria (maximum mean concentration 6.8 (SD 1.2) µg/ml at 2–4 hours post-dose). An effective concentration is maintained for at least 12 hours, the standard interdose interval for this antimicrobial.

Conclusion: Linezolid offers the possibility of a rapid, oral approach to effective treatment of most cases of postoperative endophthalmitis, with the potential of improving visual outcome.


Abbreviations: HPLC, high performance liquid chromatography; MIC, minimal inhibitory concentration; POE, postoperative endophthalmitis

Keywords: linezolid; pharmacokinetics; endophthalmitis







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 by the BMJ Publishing Group Ltd.